8-K: Alumis Reports Q3 2025 Results, Anticipates Key Data Readouts

Alumis Inc. reported its third-quarter 2025 financial results, highlighting pipeline advancements and anticipating significant clinical data readouts for envudeucitinib in early Q1 2026 and Q3 2026.

Summary

• Net loss for the third quarter of 2025 was $110.8 million, compared to a net loss of $93.1 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities totaled $377.7 million as of September 30, 2025.
• Collaboration revenue for Q3 2025 was $2.1 million, related to an agreement with Kaken Pharmaceutical Co., Ltd.
• Research and development expenses increased to $97.8 million in Q3 2025 from $87.8 million in Q3 2024, driven by accelerated clinical trial activities for the Phase 3 ONWARD program, merger-related costs, and increased headcount.
• General and administrative expenses rose to $19.5 million in Q3 2025 from $10.6 million in Q3 2024, primarily due to merger-related costs and support for company growth.
• Total expenses related to the merger with ACELYRIN were $6.3 million for Q3 2025 and $40.8 million for the nine months ended September 30, 2025.
• Topline Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis is expected early in the first quarter of 2026.
• Topline Phase 2b LUMUS data for envudeucitinib in systemic lupus erythematosus is expected in the third quarter of 2026.
• Initiation of a Phase 2 clinical trial for A-005 in multiple sclerosis is anticipated in the first half of 2026.
• Existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditure requirements into 2027.

Sentiment

Score: 6

Explanation: While financial losses and expenses increased, this is typical for a clinical-stage biopharma company heavily investing in R&D. The significant pipeline progress, positive data publications, and clear upcoming milestones, coupled with a cash runway into 2027, provide a generally positive outlook despite the increased burn rate. The merger-related expenses are one-off in nature.

Positives

• Advancement of envudeucitinib pipeline with anticipated key Phase 3 and Phase 2b data readouts in early Q1 2026 and Q3 2026, respectively.
• Publication of positive Phase 2 STRIDE clinical trial results for envudeucitinib in moderate-to-severe plaque psoriasis in the Journal of the American Academy of Dermatology (JAAD), demonstrating sustained or increasing response rates and a well-tolerated safety profile.
• Positive poster presentation for A-005, a CNS-penetrant TYK2 inhibitor, at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, showing a favorable pharmacokinetic profile, maximal TYK2 inhibition, blood-brain barrier penetration, and good tolerability.
• Positive poster presentation for lonigutamab, an anti-IGF-1R therapy, at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) annual meeting, highlighting its differentiated mechanism of action, safety profile, and potential in thyroid eye disease.
• Strong cash position with $377.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Financial guidance indicates existing cash supports operations into 2027, through multiple planned key clinical data readouts.

Negatives

• Net loss increased to $110.8 million for the third quarter of 2025, compared to $93.1 million for the same period in 2024.
• Research and development expenses increased by $10.0 million to $97.8 million in Q3 2025, reflecting higher clinical trial costs and merger-related expenses.
• General and administrative expenses increased by $8.9 million to $19.5 million in Q3 2025, primarily due to merger-related costs and personnel expenses.
• Significant merger-related expenses from the ACELYRIN merger, totaling $6.3 million in Q3 2025 and $40.8 million year-to-date, contributed to increased operating costs.

Risks

• Ability to advance envudeucitinib or other programs and to obtain regulatory approval of and ultimately commercialize clinical candidates.
• The timing and results of preclinical and clinical trials may not be favorable or as anticipated.
• Ability to fund development activities and achieve development goals.
• Ability to protect intellectual property.
• Actual results, levels of activity, safety, efficacy, performance, or events and circumstances could differ materially from forward-looking statements.

Future Outlook

Alumis anticipates significant clinical milestones, including topline Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis early in the first quarter of 2026, and topline Phase 2b LUMUS data in systemic lupus erythematosus in the third quarter of 2026. The company expects to establish a once-daily formulation for envudeucitinib in 2025 and initiate a Phase 2 clinical trial for A-005 in multiple sclerosis in the first half of 2026. Phase 1 clinical data for a third internally-developed program is projected for the second half of 2026. Alumis's existing cash, cash equivalents, and marketable securities are expected to fund operations into 2027.

Management Comments

• "As we continue to advance our pipeline, we are entering an important period for Alumis. Our teams have been working diligently, and we are eagerly anticipating key milestones ahead with topline Phase 3 ONWARD data for envudeucitinib (envu) in moderate-to-severe plaque psoriasis (PsO) expected to be announced early in the first quarter of 2026, followed by topline Phase 2b LUMUS data in systemic lupus erythematosus (SLE) in the third quarter."
• "These data readouts have the potential to validate envus differentiated profile and unlock broader opportunities across immune-mediated diseasesrepresenting meaningful inflection points for both the company and the patients we aim to serve."
• "Our robust pipeline, spanning late-stage, clinical programs and advanced preclinical candidates, reflects the strength of our precision immunology R&D platform and our mission to transform the treatment landscape for immune-mediated diseases. Leveraging a validated mechanism with broad therapeutic potential, our two next-generation oral TYK2 inhibitor programs position us well to advance on this mission."

Industry Context

The biopharmaceutical industry continues to prioritize the development of targeted therapies for immune-mediated diseases, with TYK2 inhibitors emerging as a key class due to their potential for improved efficacy and safety profiles. Alumis's focus on next-generation oral TYK2 inhibitors, including envudeucitinib for systemic disorders and A-005 for neuroinflammatory diseases, positions it within a highly competitive but innovative segment. The anticipated clinical data readouts for its lead programs are crucial for validating its precision immunology platform and establishing its competitive standing against other companies developing similar or competing therapies in areas like psoriasis, lupus, and multiple sclerosis.

Stakeholder Impact

• Shareholders face increased losses and R&D expenses, but also potential for significant value creation if upcoming clinical trials are successful. The cash runway into 2027 provides financial stability through key milestones.
• Employees in R&D teams have increased headcount, indicating growth, but the mention of severance costs related to the ACELYRIN merger suggests some personnel adjustments.
• Patients with immune-mediated diseases (e.g., psoriasis, lupus, multiple sclerosis, thyroid eye disease) could benefit from new, differentiated therapeutic options if Alumis's pipeline candidates prove successful.
• Creditors and suppliers are indirectly impacted by increased R&D spending, implying continued engagement with contract research organizations and other service providers.

Next Steps

• Announce topline Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis (early Q1 2026).
• Announce topline Phase 2b LUMUS data for envudeucitinib in systemic lupus erythematosus (Q3 2026).
• Establish a once-daily formulation for envudeucitinib (2025).
• Initiate a Phase 2 clinical trial for A-005 in multiple sclerosis (H1 2026).
• Continue evaluation of the lonigutamab development program.
• Anticipate Phase 1 clinical data for a third internally-developed program (H2 2026).

Key Dates

Recommendation

The company reported increased losses and expenses, which is typical for a clinical-stage biopharma company heavily investing in its pipeline. However, the significant upcoming clinical data readouts for envudeucitinib in Phase 3 (PsO) and Phase 2b (SLE) in early Q1 2026 and Q3 2026, respectively, represent major inflection points. The cash runway into 2027 provides sufficient funding through these critical milestones. Investors should hold their positions to await these highly determinative data readouts, which will significantly influence future valuation. Positive Phase 2 data and preclinical results for other candidates are encouraging, but the near-term focus remains on the envudeucitinib results.

Keywords

Biopharmaceutical, Clinical-stage, Immune-mediated diseases, TYK2 inhibitor, Envudeucitinib, Plaque psoriasis, Systemic lupus erythematosus, A-005, Multiple sclerosis, Lonigutamab, Thyroid eye disease, Financial results, Q3 2025, Pipeline, Clinical trials, R&D, Nasdaq: ALMS